Cytochrome P450dbl phenotypes in malignant and benign breast disease

European Journal of Cancer and Clinical Oncology

Volumn 26, Issue 7, 1990, Pages 790-792

  Pontin, J E ^a   Hamed, H ^b   Fentiman, I S ^b   Idle, J R ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DEBRISOQUINE;

ARTICLE; BREAST CANCER; BREAST DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL;

ADULT; BREAST DISEASES; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEBRISOQUIN; FEMALE; GENETIC MARKERS; HUMAN; MIDDLE AGE; MIXED FUNCTION OXYGENASES; PHENOTYPE;

EID: 0025037307     PISSN: 02775379     EISSN: None     Source Type: Journal    
DOI: 10.1016/0277-5379(90)90153-K     Document Type: Article

References (20)

1. Hormones and other factors controlling growth in the mammary gland
2. Fat tissue: a steroid reservoir and site of steroid metabolism
3. Estrogenic potency, receptor interactions and metabolism of catechol estrogens in immature rat uterus in vitro
4. Kinetics of estrogen-estrogen receptor dissociation: a possible factor underlying differences in catechol estrogen biological activity
5. Catecholestrogens: chemistry, biosynthesis, metabolism, occurrence and physiological significance
6. Identification of organic hydroperoxide dependant catecholestrogen formation by placental microsomes: comparison with alternative NADPH dependent pathway
7. Perioxidatic catecholestrogen production by human breast cancer tissue in vitro
8. The P450 gene superfamily: recommended nomenclature
9. P450 genes: structure, evolution and regulation
10. Absence of hepatic cytochrome P450 buf 1 causes genetically deficient debrisoquine oxidation in man
11. Polymorphic hydroxylation of debrisoquine in man
12. A family and population study of the genetic polymorphism of debrisoquine oxidation in a British white population
13. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer
14. Debrisoquine metabolic phenotype (MP), asbestos exposure and lung cancer
15. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors
16. Debrisoquine oxidation phenotype and susceptibility to lung cancer
17. Genetically determined debrisoquine oxidation capacity in bladder cancer
18. Chemical and biological stability of the debrisoquine metabolic ratio
19. Influence of smoking on the distribution of the debrisoquine metabolic ratio
20. Risk factors for breast cancer in women with proliferative breast disease